Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FF-10158
- Development stage
- Unknown
- Lead developer
- Advanced Accelerator Applications
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
FF-10158 is a radioligand therapy under clinical development for the treatment of several cancers, including recurrent glioblastoma multiforme (GBM), pancreatic ductal adenocarcinoma, and gastroesophageal adenocarcinoma. The drug consists of the small molecule FF-10158 radiolabeled with either lutetium 177 or gallium 68 isotopes. Its mechanism of action involves targeting integrin alpha V (ITGAV), integrin beta 3 (ITGB3), and integrin beta 5 (ITGB5) on tumor cells. The lutetium-labeled version is being developed as a therapeutic agent emitting ionizing radiation to kill cancer cells, while the gallium-labeled version serves as a diagnostic agent for positron emission tomography imaging. The drug is administered parenterally and was originally developed by FUJIFILM Holdings but is now being advanced by Advanced Accelerator Applications, a subsidiary of Novartis[1][2][3][4][5][7][8].
- Other names
- Lutetium 177-labeled FF-10158Lutetium177-labeled FF-10158Lutetium-177-labeled FF-10158Gallium 68-labeled FF-10158Gallium68-labeled FF-10158Gallium-68-labeled FF-10158
02
Targets
αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)
Beyond the preview
Go deeper on FF-10158.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FF-10158.